Picture supply: Getty Pictures
Airtel Africa (LSE: AAF) is the top-performing FTSE 100 inventory in my portfolio at present and it’s already gained an additional 10% this month.
One other considered one of my favourites, albeit nowhere close to the highest, is GSK (LSE: GSK). After months of declines, the healthcare group has been making a restoration. It’s up a powerful 11.6% over the previous month.
They’re very totally different corporations however each provide distinctive qualities, every serving to to bolster my portfolio in their very own method.
An surprising development alternative
As an investor who prefers the protection of defensive earnings shares, Airtel Africa is an odd alternative for me. The telecoms supplier operates in what many would contemplate dangerous areas on the African continent.
Nevertheless, the danger has paid off. Up virtually 200% prior to now 12 months, the inventory is outshining even the most important S&P 500 tech giants in my portfolio.
Sadly, the expansion will not be sustainable. The current surge appears largely as a consequence of easing forex change pressures and tariff will increase in Nigeria. Those self same pressures may simply flip again within the different route in such a risky area. That’s a key threat I have to control.
Nonetheless, sturdy financials are backing a few of the development. Half-year income rose about 26% to just about $3bn, whereas revenue after tax climbed to $376m. With a quickly increasing community, rising margins and rising dividends, it appears to be heading in a very good route.
The worth could also be a bit overvalued now but it surely’s nonetheless price contemplating for its long-term prospects in Africa.
Resilient healthcare
The biotechnology agency’s worth was boosted by a powerful set of third-quarter outcomes and an improved outlook for 2025. The corporate reported gross sales of £8.5bn, up round 7% 12 months on 12 months, with significantly sturdy efficiency from its Speciality Medicines division, which grew 16% to £3.4bn.
Its oncology gross sales had been a standout success, surging almost 39%. That shines a lightweight on the rising power of its new drug portfolio after offloading its prescribed drugs arm.
The efficiency is supported by encouraging medical updates, significantly for its respiratory biologics and RSV vaccine.
However I didn’t purchase GSK shares for his or her development prospects. They’re meant so as to add defensiveness to my portfolio, together with a good little bit of earnings from the three.6% dividend yield.
Whereas the expansion is welcome, historical past exhibits that the inventory is extremely cyclical and can seemingly dip once more within the coming 12 months. Nonetheless, for earnings and defensiveness, it’s a worthy consideration, in my e-book.
Remaining ideas
It’s unattainable to precisely predict the route of shares. At instances, I’ve been pleasantly stunned, at others, I’ve been sadly dissatisfied.
That’s why I preserve a extremely diversified portfolio of shares from a variety of industries. These two have completed nicely this month however may simply slip within the subsequent.
Nevertheless, total, my portfolio usually enjoys regular development as every sector and inventory performs its half.
